Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai Huanma Biomedicine

Request full access

A biomedical company that develops nucleic acid drugs based on a unique circular RNA technology platform

Huangpu, ChinaFounded 2021Biotech & Life Sciences

About Shanghai Huanma Biomedicine

Shanghai Huanma Biomedicine, also known as CirCode Biomed, is a biopharmaceutical company established in 2021, specializing in the development of nucleic acid drugs through its proprietary circular RNA (circRNA) technology platform. The company was scientifically founded by Professor Wang Zefeng, who serves as the chairman. Professor Wang's extensive academic journey includes a dual degree in life sciences and computer science from Tsinghua University, a Ph.D. in biochemistry from Johns Hopkins University, and postdoctoral research at MIT. His two decades of research in RNA molecular and computational biology, particularly the groundbreaking discovery in 2014 that circRNA can be translated into proteins in human cells, forms the scientific bedrock of the company.

The co-founder and CTO, Dr. Yang Yun, holds a Ph.D. in molecular biology and biochemistry from Zhejiang University and has years of experience in RNA processing and translation control. The management team is further strengthened by CEO Dr. Tang Chenxiang, who brings over a decade of biopharmaceutical R&D and operational experience. The company's core focus is to leverage the unique properties of circRNA to overcome the limitations of traditional linear mRNA therapies. Unlike linear mRNA, the closed-loop structure of circRNA offers greater stability, making it resistant to degradation by enzymes, and is associated with lower immunogenicity. This allows for more sustained protein expression, positioning circRNA as a promising next-generation platform for therapeutics.

CirCode Biomed is advancing a pipeline of novel therapies aimed at unmet medical needs. Its business model revolves around the research and development of these circRNA-based drugs, with a goal of commercialization. The company has successfully secured significant funding to advance its mission. Following a nearly $10 million angel round in June 2021, it raised over $20 million in a Pre-A round in December 2021 and secured a multi-million dollar Series A round in August 2023, led by notable investors including Johnson & Johnson Innovation (JJDC). In August 2024, the company announced the first-in-human investigator-initiated trial for its candidate HM2002, a gene therapy for therapeutic angiogenesis in patients with ischemic heart failure. CirCode operates from its integrated R&D and production base in Shanghai's Waigaoqiao Free Trade Zone, which supports its pipeline from discovery to cGMP manufacturing.

Source: Dealroom company data

At a glance

Status
Operational
Employees
8
Open positions
None listed
Dealroom signal
80.9/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Aug 2023 — — Johnson & Johnson Innovation · Superstring Capital ↗
SEED✓Equity / VC Dec 2021 $20M $80M Kaitai Capital · Cowin Capital · Kunlun Capital ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Shanghai Huanma Biomedicine website traffic

Latest recorded traffic for Shanghai Huanma Biomedicine is 550 monthly website visits, up 243.8% over the last three months. Shanghai Huanma Biomedicine's team grew 0% over the past year.

Latest monthly visits550 3-month web change+243.8% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shanghai Huanma Biomedicine in the Huangpu ecosystem

Live from Dealroom

The Shanghai Huanma Biomedicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Kaitai Capital
  • Cowin Capital
  • Kunlun Capital

Series A2 investors entered at this stage

  • Johnson & Johnson Innovation
  • Superstring Capital

Other known investors1 additional known investor

  • University of Chinese Academy of Sciences
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China83.3%
🇦🇺 Australia16.7%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai Huanma Biomedicine on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Huanma Biomedicine’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.